All references in this report to Corbus, the Company, we, us, or our mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Overview Corbus Pharmaceuticals Holdings, Inc. (the Company or Corbus) is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Cor...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001193125-26-098530 | EDGAR | 71K words |
| 2025-03-11 | 2024-12-31 | 0000950170-25-037335 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0000950170-24-030133 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0000950170-23-006469 | EDGAR | — |
| 2022-03-08 | 2021-12-31 | 0000950170-22-003145 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001493152-21-006016 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001493152-20-004077 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001493152-19-003143 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001493152-18-003208 | EDGAR | — |
| 2017-03-08 | 2016-12-31 | 0001493152-17-002256 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277748 | EDGAR | 19K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103118 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064507 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123486 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091922 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054625 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060377 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039960 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019825 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023282 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016150 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-009050 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001193125-26-097582 | EDGAR | 2K words |
| 2026-02-25 | 0001193125-26-068566 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009758 | EDGAR | — |
| 2025-12-18 | 0001193125-25-324796 | EDGAR | — |
| 2025-12-11 | 0001193125-25-315039 | EDGAR | — |
| 2025-11-12 | 0001193125-25-276062 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261722 | EDGAR | — |
| 2025-10-30 | 0001193125-25-258692 | EDGAR | — |
| 2025-10-20 | 0001193125-25-243046 | EDGAR | — |
| 2025-09-16 | 0001193125-25-204389 | EDGAR | — |
260 total filings indexed. 228 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001595097 |
| Ticker | CRBP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.corbuspharma.com |
| Listed | 2014-10-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report